Scientific Committee

Chairperson

Bruno FALISSARD	Université Paris Sud

Members

Marisa BACCHI	Actelion
Luc BIJNENS	Johnson and Johnson
Frank BRETZ	Novartis
Peter BÜHLMANN	ETH Zurich
Antoine CHAMBAZ	Université Paris Nanterre
Jelle GOEMAN	LUMC
Stefan MICHIELS	INSERM
Martin POSCH	Medical University of Vienna
Pascale TUBERT-BITTER	INSERM

Organizing Committee

Chairperson

Sophie GUILLONNEAU	Sanofi

Members

Ismaïl AHMED	INSERM
Chantal DIN-BELL	Sanofi
Frédéric DUBOIS	Servier
Nadia GAUDEL-DEDIEU	Sanofi
Karine LE MALICOT	FFCD
Alexia LETIERCE	Sanofi
Fabienne MEURICE	Ewentis
Philippe SAINT-PIERRE	Université Toulouse III
Michel VAILLANT	LIH
Françoise VEYRIAC	Lincoln & Aixial
Laurence WATIER	INSERM

All information will be available on the Web site:

www.smb2017.fr

This meeting will focus on the latest progress in selected statistical topics of high relevance to clinical drug development.

The Scientific Committee, chaired by **Pr Bruno FALISSARD**, has identified four areas of research that may change the face of clinical drug development in the near future:

- **Regulatory statistics and beyond**
- **Statistical inference in biostatistics of the XXIst century**
- **Successful marriage between bioinformatics and biostatistics**
- **Recurrent event analyses**

Contributed papers will be welcome for an oral presentation if they are relevant to any of these areas, or as a poster presentation if they describe unrelated but innovative research on clinical drug development.

All invited and selected papers may be submitted for publication in a special issue of Statistics in Medicine.

8th SFdS
SOCIETE FRANÇAISE DE STATISTIQUE
GROUPE BIOPHARMACIE ET SANTE

INTERNATIONAL MEETING

Statistical Methods in Biopharmacy

"THE FUTURE OF BIOSTATISTICS IN AN EMERGING WORLD OF DATA SCIENCES"

2017
September
14 - 15

NEW CAP
Event Center
1-13 quai de Grenelle
PARIS

"THE FUTURE OF BIOSTATISTICS IN AN EMERGING WORLD OF DATA SCIENCES"

DAY 1: Thursday 14 September, 2017

Regulatory statistics and beyond

Biological treatments with clear-cut mechanism of action, small targeted populations challenge the way regulatory authorities evaluate drugs. Post approval, including market access and pricing implies studies, data and analyses that differs substantially from the routine of large phase 3 randomized controlled trials.

Bruno FALISSARD,
Université Paris Sud
Post-approval appraisal: What are the main methodological issues?

Stephen J. RUBERG, Eli Lilly and Company
Disruptive approaches for clinical trials pre- and post-approval

Statistical inference in biostatistics of the XXIst century

Statistical inference is the corner stone of biostatistics. The quiet situation that characterized the end of the XXIst century, with the prominence of the very orthodox Neyman-Pearson background, is now over. Even if this important change has been due, in part, to the rise of omics data and of the Bayesian perspective, new research put some interesting light on this crucial question.

Hans van HOUWELINGEN, LUMC
(Leiden University Medical Center)
The future of biostatistics: Robust prediction!

Antoine CHAMBAZ, Université Paris Ouest
The future of biostatistics: Targeted learning in action

DAY 2: Friday 15 September, 2017

Successful marriage between bioinformatics and biostatistics

Biostatistics was not traditionally involved in data sets counting more than millions of variables, so that omics data opened the door to "newcomers" among which bioinformatics professionals. There is a need to think a global framework in which a marriage between bioinformatics and biostatistics can be considered. Practical examples will surely help to think such framework.

Jean-Philippe VERT,
Institut Curie, Mines ParisTech & ENS Paris
Identifying predictive biomarkers in high-dimensional genomic data from randomized clinical trials

Jelle GOEMAN, LUMC (Leiden University Medical Center)
New directions in multiple testing of biomarkers: Flexible approaches with rigorous control

Recurrent event analyses

Cancer, HIV, cardiac or psychiatric diseases are now most often chronic situations. Outcomes collected in trials have thus changed and, most often, they can no more be considered as simply as "success or failure". This raises the question of "recurrent event analysis", a technical but well formulated problem for which many solutions do exist now.

Richard COOK, University of Waterloo
Yujie ZHONG, University of Cambridge
Marginal and partially conditional analysis of recurrent events in clinical trials

Mouna AKACHA, Novartis
Are we making good use of our data: Moving beyond time-to-event data

Venue

Métro: Bir Hakeim (line 6)
RER C: Champ-de-Mars / Tour Eiffel

Organization

The conference will be organized with four plenary sessions and two sessions dedicated to poster presentations (exclusively size landscape). Each plenary session will alternate invited and contributed papers. Three contributed papers related to each area of interest will be selected for oral presentation. Two poster sessions will present a limited number of selected contributed papers.
The working language will be English (papers, posters and oral presentations).

Key Dates

Opening of abstract submission ..... November, 2016
Deadline for abstract submission.....28 February, 2017
Notification of abstract acceptance..... 31 May, 2017
Submission of final presentation.....31 August, 2017
Submission of papers for publication..... November, 2017

Opening of registration ..... November, 2016
Deadline for early registration..... 1 June, 2017

Registration Fees

	Reduced*	Standard
	Before 1 June, 2017	
Academic	350€	420€
Non Academic	650€	720€
	After 1 June, 2017	
Academic	450€	520€
Non Academic	850€	920€
Student	80 € **	150 € **

* Reduced prices for
- SFdS Members
- Selected speakers and posters (early registration fees)

** Student with document in proof.